Eli Lilly Stock Is Rising Monday: What's Going On?
Eli Lilly Stock Is Rising Monday: What's Going On?
"Today, many cases of OSA go undiagnosed and untreated, leaving millions at risk for serious health consequences," said Eli Lilly and Company (NYSE:LLY) shares are trading higher Monday. The upward momentum in the stock comes after the FDA approved the company's Zepbound, a weight loss drug designed to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
禮來公司（紐交所：LLY）股票在週一交易中上漲。股價的上漲勢頭是因爲FDA批准了該公司的Zepbound，這是一種用於治療肥胖成年人中度至重度 obstructive sleep apnea 的減重藥物。
What To Know: After the market close on Friday, Eli Lilly announced FDA approval of Zepbound (tirzepatide) as the first prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity.
重要信息：在週五市場收盤後，禮來宣佈Zepbound（tirzepatide）獲得FDA批准，成爲首個用於治療中度至重度 obstructive sleep apnea 和肥胖的處方藥。
Obstructive sleep apnea is estimated to affect 50 million to 80 million people in the U.S., with an estimated 20 million suffering from moderate-to-severe forms. Clinical trials demonstrated the drug's efficacy, with nearly half of patients on the highest dose showing significant improvement in their apnea-hypopnea index, a primary diagnostic metric.
據了解，阻塞性睡眠呼吸暫停在美國影響約5000萬至8000萬的人，估計有2000萬人患有中度至重度的形式。臨牀試驗顯示，該藥物有效，近一半在最高劑量下的患者在其apnea-hypopnea指數上顯示出顯著改善，這是一個主要的診斷指標。
"Today, many cases of OSA go undiagnosed and untreated, leaving millions at risk for serious health consequences," said Patrik Jonsson, executive vice president, and president of Lilly Cardiometabolic Health and Lilly USA. "Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity."
禮來心血管代謝健康及禮來美國總裁Patrik Jonsson表示：「如今，許多阻塞性睡眠呼吸暫停的案例未被診斷和治療，使得數百萬人面臨嚴重的健康風險。Zepbound是第一種顯著改善中度至重度阻塞性睡眠呼吸暫停並幫助肥胖成年人長期減重的藥物。」
The approval is expected to impact insurance coverage for Zepbound, potentially expanding Medicare benefits for obesity-related treatments. In addition to improved obstructive sleep apnea symptoms, adults on Zepbound lost an average of 45 lbs (18%) of their body weight in Phase 3 trials.
這一批准預計將影響Zepbound的保險覆蓋，可能擴展醫療保險對肥胖相關治療的福利。根據第3期試驗，服用Zepbound的成年人平均減重45磅（18%）。
The approval also positions Eli Lilly ahead of competitors like Novo Nordisk, whose Wegovy lacks approval for sleep apnea. The company's ongoing $3 billion investment in manufacturing capacity underscores its focus on meeting demand for its diabetes and obesity treatments.
這一批准也使得禮來在競爭對手如諾和諾德（Novo Nordisk）之前走在了前面，其Wegovy尚未獲得睡眠呼吸暫停的批准。該公司正在進行30億的製造能力投資，顯示其致力於滿足糖尿病和肥胖治療的需求。
Eli Lilly reported third-quarter revenue of $11.44 billion in October, reflecting a 20% year-over-year increase. Zepbound accounted for approximately $1.26 billion in total revenue during the quarter.
禮來在10月份報告了第三季度營業收入爲114.4億美元，同比增長20%。在這一季度，Zepbound貢獻了約12.6億美元的總收入。
LLY Price Action: Eli Lilly shares were up 3.11% at $791.63 at the time of writing, according to Benzinga Pro.
LLY股價動態：根據Benzinga Pro，禮來股票在撰寫時上漲了3.11%，目前價格爲791.63美元。
- Pfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
- 輝瑞在C. diff生物-疫苗和肺炎球菌疫苗上的進展贏得了分析師的信心。
Image Via Shutterstock.
圖片來自Shutterstock。
譯文內容由第三人軟體翻譯。
